Rebamipide
From Wikipedia, the free encyclopedia
Rebamipide
|
|
Systematic (IUPAC) name | |
2-[(4-Chlorobenzoyl)amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid | |
Identifiers | |
CAS number | |
ATC code | ? |
PubChem | |
Chemical data | |
Formula | C19H15Cl2O4 |
Mol. mass | 370.786 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Rebamipide, an amino acid derivative of 2(1H)-quinolinone, is used for mucosal protection, healing of gastroduodenal ulcers, and treatment of gastritis. It works by enhancing mucosal defense, scavenging free radicals, and temporarily activating genes encoding cyclooxygenase-2.
It has also been used for the treatment of Behçet's disease.
[edit] References
- Arakawa T, Watanabe T, Fukuda T, Yamasaki K, Kobayashi K (1995). "Rebamipide, novel prostaglandin-inducer accelerates healing and reduces relapse of acetic acid-induced rat gastric ulcer. Comparison with cimetidine". Dig Dis Sci 40 (11): 2469–72. doi: . PMID 7587834.
- Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A (1998). "Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing". Dig Dis Sci 43 (9 Suppl): 5S–13S. PMID 9753220.
- Matsuda T, Ohno S, Hirohata S, Miyanaga Y, Ujihara H, Inaba G, Nakamura S, Tanaka S, Kogure M, Mizushima Y (2003). "Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behcet's disease: a randomised, double-blind, placebo-controlled study". Drugs R D 4 (1): 19–28. doi: . PMID 12568631.
- Tarnawski AS, Chai J, Pai R, Chiou SK (2004). "Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action?". Dig Dis Sci 49 (2): 202–9. doi: . PMID 15104358.